Book Value per Share: Verona Pharma plc (VRNA)

The commercialization of the COPD inhalant by Verona Pharma plc (VRNA) is driving operating leverage growth and the recoupment of R&D costs. The drug Ohtuvayre creates a closed therapeutic loop for pulmonologists with no existing equivalents. The book value per share on the current GURU.Markets platform chart shows that the value of 3.26 expresses the metric level. The strategy is based on pairing innovative molecules with proprietary nebulizers for precise drug delivery.

Verona Pharma PLC (VRNA): Share Book Value from 07/04/2022 to 10/18/2025

veronapharma.com - analytical breakdowns and key metrics (VRNA)

- price and consensus price forecast:

Price Chart Verona Pharma Corp|VRNA - Broker Consensus Forecast

- market capitalization data:

Market Capitalization Verona Pharma plc|VRNA - Enterprise Value

- book capitalization data:

Net Assets per Single Share Verona Pharma|VRNA - Net Asset Value|Market Capitalization to Book Value Ratio veronapharma.com|VRNA - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Verona Pharma plc|VRNA - Long-Term Debt to Capital|Short-Term Debt to Equity Verona Pharma|VRNA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Verona Pharma plc

Fundamental company valuation:Verona Pharma Corp - VRNA

Book value per share determines the actual value of net assets available to the holder of each security. The trend in the calculated book value per share reveals the gap between market quotes and the asset base. This metric is calculated by dividing equity minus liabilities by the number of shares. Growth in this metric confirms the business capitalization. For Verona Pharma plc (VRNA), this is supported by the commercial success of Ensifentrine and the protection of margins via patents.

Competitors of Verona Pharma plc (VRNA)

Haleon Group (HLN) - Net Assets per Single Share|KVUE - Equity per Share|MENS: Book Value per Share|LGND (ligand.com) - Book Value per Share|Net Assets per Single Share Amneal AMRX|Share Book Value Perrigo Company PLC|Alvotech Corp (ALVO) - Book Value per Share|Accounting Value of a Share Liquidia Inc. (LQDA)|Book Value per Share GLPG (Galapagos NV)|anipharmaceuticals.com - Book Value per Share|Net Assets per Single Share MannKind (MNKD)|AMPH: Accounting Value of a Share|PCRX (Pacira) - Net Assets per Single Share|ARS Corp (SPRY) - Accounting Value per Share|TBPH (Theravance Biopharma) - Book Value per Share|Book Value per Share aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Accounting Value per Share|Accounting Value of a Share TECX (tectonictx.com)|TNXP: Net Assets per Single Share|SXTC - Net Asset Value per Share|Accounting Value per Share Eupraxia Pharma EPRX|BHST - Book Price of a Share|Book Value per Share eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Accounting Value of a Share|Book Value per Share ENTX (Entera Bio Ltd)|Net Asset Value per Share HYFT|ABVC BioPharma (ABVC) - Net Assets per Single Share|Accounting Value of a Share cumberlandpharma.com CPIX|Accounting Value per Share Quantum BioPharma QNTM|Net Assets per Single Share FibroGen Inc FGEN|TELO (Telomir Pharma) - Book Value per Share|RANI: Net Asset Value per Share|Net Assets per Single Share synergychc.com SNYR|RLYB (Rallybio) - Accounting Value of a Share|Net Assets per Single Share LEXX (Lexaria Bioscience Corp)|Net Asset Value per Share PULM|Net Assets per Single Share Pheton Holdings Ltd PTHL|Equity per Share aptorumgroup.com (APM)|Book Value per Share LYRA (Lyra Therapeutics, Inc.)|IBO - Book Value per Share|Accounting Value per Share TNF Pharma (TNFA)|YCBD: Accounting Value of a Share|Net Assets per Single Share PainReform Limited (PRFX)|Altamira Therapeutics Ltd. (CYTO) - Share Book Value|LIPO - Book Value per Share|Accounting Value of a Share optinose.com|Book Value per Share PIRS|Book Value per Share PROC (Procaps Group)|Net Assets per Single Share Petros|Qilian International Corp - Accounting Value of a Share|SLRN: Net Assets per Single Share|TFFP - Accounting Value per Share